Intrexon Enters into Technology Collaboration to Advance Animal Health Applications
BeyondBio(TM) Platform Enhances The Design and Engineering Process of Biological Solutions
GERMANTOWN, Md., July 29, 2014 /PRNewswire/ — Intrexon Corporation (NYSE: XON), a leader in synthetic biology, has further enhanced its collaboration with a global animal health company to enable remote access to Intrexon’s suite of technologies via its groundbreaking BeyondBio(TM) platform.
Dana Di Ferdinando, Intrexon’s Chief Information Officer commented, “We are very pleased to announce this technology collaboration with our partner. We believe that the BeyondBio(TM) portal will facilitate faster and more efficient collaboration between our companies, and provide the ability to create leading-edge therapeutic products to improve animal health from their desktops with an intuitive, easy-to-use interface.”
The BeyondBio(TM) platform combines the principles of precision engineering, statistical modeling, automation, and lean production to power the next generation of optimized biological designs for unique DNA-based solutions across broad markets. With untethered access to Intrexon’s extensive library of proprietary DNA parts, including the clinically validated RheoSwitch(®) system and AttSite(®) recombinases, this gateway affords its collaboration partner the unique flexibility to develop customizable biologically-based therapeutic products to better animal health from their own facilities with an integrated end-to-end solution.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create biologically-based products that improve the quality of life and the health of the planet. Through the company’s proprietary UltraVector(®) platform and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector(®) platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA(®), and we invite you to discover more at www.dna.com.
Intrexon, BeyondBio, UltraVector, RheoSwitch, AttSite, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Intrexon’s current expectations and projections about future events and generally relate to Intrexon’s plans, objectives and expectations for the development of Intrexon’s business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. These risks and uncertainties include, but are not limited to, (i) Intrexon’s current and future ECCs and joint ventures; (ii) developments concerning Intrexon’s collaborators; (iii) Intrexon’s ability to successfully enter new markets or develop additional products, whether with its collaborators or independently; (iv) competition from existing technologies and products or new technologies and products that may emerge; (v) actual or anticipated variations in Intrexon’s operating results; (vi) actual or anticipated fluctuations in Intrexon’s competitors’ or its collaborators’ operating results or changes in their respective growth rates; (vii) Intrexon’s cash position; (viii) market conditions in Intrexon’s industry; (ix) Intrexon’s ability, and the ability of its collaborators, to protect Intrexon’s intellectual property and other proprietary rights and technologies; (x) Intrexon’s ability, and the ability of its collaborators, to adapt to changes in laws or regulations and policies; (xi) the ability of Intrexon’s collaborators to secure any necessary regulatory approvals to commercialize any products developed under the ECCs; (xii) the rate and degree of market acceptance of any products developed by a collaborator under an ECC; (xiii) Intrexon’s ability to retain and recruit key personnel; (xiv) Intrexon’s expectations related to the use of proceeds from its initial public offering; (xv) Intrexon’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and (xvi) Intrexon’s expectations relating to AquaBounty. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Intrexon’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intrexon’s Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intrexon’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intrexon undertakes no duty to update this information unless required by law.
For more information regarding Intrexon Corporation, contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
Vice President, Investor Relations
Tel: +1 (561) 410-7052
SOURCE Intrexon Corporation